secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0000950170-24-000543
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics effects 1-for-10 reverse stock split to maintain Nasdaq listing
--------------------------------------------------------------------------------

- Reverse split effective 12:01 a.m. ET Jan 5, 2024; reduces outstanding shares from ~92.25M to ~9.225M.
- Stockholders approved at Jan 2, 2024 special meeting with 59,076,836 votes for, 3,409,403 against.
- Warrants (SABSW) adjusted: every 10 warrants now exercisable for 1 share at $115.00 per share.
- New CUSIP for common stock (SABS) is 78397T202; fractional shares paid in cash.
- Split intended to bring SABS above Nasdaq minimum bid price requirement and maintain listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024000543/0000950170-24-000543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024000543/sabs-20240102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-000543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer